Antares Pharma, Inc. (ATRS)

[H2R]

New SoS entry on ATRS:

https://smithonstocks.com/antares-pharma-fda-action-to-not-approve-xyosted-on-its-october-20-2017-pdufa-date-is-perplexing-atrs-buy-2-23/

Larry cannot see the reasons behind the FDA decisions and still sees an approval, based on what he knows (i.e. he does not know the reasons behind the letter and neither does the Company).

however, he calls ATRS a Buy, even without Xyosted, and still thinks Xyosted has good chances of being approved. (when, that's another question).